Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide

Autor: Hommer, A., for The Unoprostone Adjunctive Therapy Study Group, Kapik, * B., Hommer, N. Shams Austria: Krankenanstalt Sanatorium Hera: principal investigator: A., Germany: Medizinische Hochschule Hannover: principal investigator, M. D., C. Erb, Md, König, co investigator: W., Ober, private practitioner: M., Kalb, co investigator: D., Pfeiffer, Johannes Gutenberg Universität Mainz: principal investigator: Professor N., Rosbach, co investigator: K., Benning, co investigator: H., Böhres, co investigator: A. M., private practitioner:B Schmidl, co investigator:U Dankwardt, Schmidt, Justus Liebig Universität: principal investigator: K. G., co investigator: Ch Gisa, private practitioner:R Smettan, co investigator:H Smettan Scheler, Grignolo, Federico, co investigators: Professor B. Brogliatti, Md, Rolle, Teresa, Zanini, co investigator: A., Flipse, M. D. Netherlands: St Ziekenhuis Lievensberg: principal investigator: J. P., co investigator: Th Stolwijk, Md, van der Zee Dekker, co investigator: M., Tjia, Ziekenhuis de Weezenlanden: principal investigator: K. F., coinvestigator: A. Bootsma, Md, co investigator: Postema, Verdoorn, Carolus Liduina Ziekenhuis: principal investigator: C., co investigator: C. Korver, M. D. United Kingdom: Luton, Dunstable Hospital: principal investigator, Anand, N., Frcs, Mielke, co investigator: C., Chitkara, The Walton Hospital: principal investigator: D., Frcophth, Cook, co investigator: A., Rosen, Radcliffe Infirmary: principal investigator: P., co investigator: Y. Delaney, Frcopth, co investigator: L. Lindsell, Md, Salmon, co investigator: J. F., Novartis Ophthalmics AG, F. R. C. O. p. h. t. h., Bülach, Switzerland: Beat Mertz, Phd, Yannoulis, Natalia C., Christine, Schwenninger, Jean Yves Deslandes, Hervé de Pommerol, Msc, Carsten, Cirkel, Novartis Ophthalmics, B. A., Inc, Duluth, Usa:, Rezamhaque, Phd, Md, Christine, Kubilus, Kim, Truett, Gretchen, Longcore, Frances, Kane, P. h. D.

Aims: To compare the safety and efficacy of unoprostone, brimonidine, and dorzolamide as adjunctive therapy to timolol in patients with primary open angle glaucoma or ocular hypertension. Methods: This was a randomised, double masked, parallel group,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2aac995b4389e37a3154c841145dc10
https://europepmc.org/articles/PMC1771661/

Comparing oral versus intravenous Ca administration on alleviating markers of production, metabolism, and inflammation during an intravenous lipopolysaccharide challenge in mid-lactation dairy cows.

Autor: Opgenorth J; Department of Animal Science, Iowa State University, Ames, Iowa, 50011., Goetz BM; Department of Animal Science, Iowa State University, Ames, Iowa, 50011., Rodriguez-Jimenez S; Department of Animal Science, Iowa State University, Ames, Iowa, 50011., Freestone AD; Department of Animal Science, Iowa State University, Ames, Iowa, 50011., Combs GJ; Department of Animal Science, Iowa State University, Ames, Iowa, 50011., Flemming TA; Department of Animal Science, Iowa State University, Ames, Iowa, 50011., McGill JL; Department of Veterinary Microbiology and Preventative Medicine, Iowa State University, Ames, Iowa, 50011., Gorden PJ; Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, 50011., Tikofsky L; Boehringer Ingelheim Animal Health USA Inc., Duluth, Geogia 30096., Baumgard LH; Department of Animal Science, Iowa State University, Ames, Iowa, 50011. Electronic address: baumgard@iastate.edu.

Publikováno v: Journal of dairy science [J Dairy Sci] 2024 Nov 25. Date of Electronic Publication: 2024 Nov 25.

Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study.

Autor: Behrend EN; 1Veterinary Information Network, Davis, CA., Ward CR; 2College of Veterinary Medicine, University of Georgia, Athens, GA., Chukwu V; 3Boehringer Ingelheim Animal Health USA Inc, Duluth, GA., Cook AK; 4Department of Small Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX., Kroh C; 5Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany., Lathan P; 6Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA., May J; 7Scout Bio, Philadelphia, PA., Schermerhorn T; 8Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS., Scott-Moncrieff JC; 9Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN., Voth R; 10Boehringer Ingelheim Animal Health USA Inc, St Joseph, MO.

Publikováno v: Journal of the American Veterinary Medical Association [J Am Vet Med Assoc] 2024 Aug 14; Vol. 262 (10), pp. 1343-1353. Date of Electronic Publication: 2024 Aug 14 (Print Publication: 2024).

Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.

Autor: Di H; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Pusch EA; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Jones J; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Kovacs NA; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Hassell N; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Sheth M; Division of Core Laboratory Services and Response, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Lynn KS; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Keller MW; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Wilson MM; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Keong LM; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Cui D; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Park SH; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.; Eagle Global Scientific, Inc., Atlanta, GA 30341, USA., Chau R; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Lacek KA; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Liddell JD; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Kirby MK; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Yang G; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Johnson M; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Thor S; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Zanders N; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Feng C; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Surie D; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., DeCuir J; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Lester SN; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Atherton L; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Hicks H; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.; Synergy America, Inc., Duluth, GA 30329, USA., Tamin A; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Harcourt JL; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Coughlin MM; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Self WH; Vanderbilt Institute for Clinical & Translational Research, Vanderbilt University Medical Center, Nashville, TN 37232, USA., Rhoads JP; Vanderbilt Institute for Clinical & Translational Research, Vanderbilt University Medical Center, Nashville, TN 37232, USA., Gibbs KW; Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA., Hager DN; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Shapiro NI; Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Exline MC; Department of Medicine, The Ohio State University, Columbus, OH 43210, USA., Lauring AS; Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109, USA., Rambo-Martin B; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Paden CR; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Kondor RJ; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Lee JS; Division of Core Laboratory Services and Response, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Barnes JR; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Thornburg NJ; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Zhou B; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Wentworth DE; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA., Davis CT; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.

Publikováno v: Vaccines [Vaccines (Basel)] 2024 May 07; Vol. 12 (5). Date of Electronic Publication: 2024 May 07.

The wildland firefighter exposure and health effect (WFFEHE) study: cohort characteristics and health behavior changes in context.

Autor: Scott KA; United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Western States Division, Denver, CO, USA., Wingate KC; Synergy America, Inc., Duluth, GA, USA., DuBose KN; United States Department of the Interior, Office of Wildland Fire, Denver, CO, USA., Butler CR; United States Department of the Interior, Office of Occupational Safety and Health, Denver, CO, USA., Ramirez-Cardenas A; United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Western States Division, Denver, CO, USA., Hale CR; United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Western States Division, Denver, CO, USA.

Publikováno v: Annals of work exposures and health [Ann Work Expo Health] 2024 Feb 20; Vol. 68 (2), pp. 122-135.